Requirement of chondroitin sulfate/dermatan sulfate recognition in midkine-dependent migration of macrophages

被引:38
作者
Hayashi, K [1 ]
Kadomatsu, K [1 ]
Muramatsu, T [1 ]
机构
[1] Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan
关键词
chondroitin sulfate; macrophagemigration; midkine; protein tyrosine phosphatase zeta;
D O I
10.1023/A:1014864131288
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Midkine (MK) is a heparin-binding growth factor that promotes cell migration, cell growth and cell survival. The promotion of migration of inflammatory cells, especially macrophages, by MK is involved in formation of a vascular abnormality, i.e. neointima formation. MK-induced migration of peritoneal exudate macrophages was inhibited by heparin, chondroitin sulfate E and dermatan sulfate, but not by chondroitin sulfate D or chondroitin 6-sulfate. Digestion of macrophages with chondroitinase ABC as well as chondroitinase B decreased the migratory activity. However, heparitinase digestion showed only slight effects. These results indicated that a chondroitin sulfate, i.e. an E-type oversulfated structure with dermatan sulfate domain, is involved in MK-induced migration of macrophages. Although a chondroitin sulfate proteoglycan, receptor-type protein tyrosine phosphatase zeta (PTP zeta), participates in MK-induced migration of neurons and osteoblasts, PTP zeta was not detected in macrophages. The MK-induced migration was inhibited by PP1, wortomanin, PD 98059 and vanadate, indicating that the downstream signaling system, which includes Src, PI3 kinase and ERK as important components, is shared with other MK signaling systems in which PTP zeta is involved.
引用
收藏
页码:401 / 406
页数:6
相关论文
共 32 条
[1]
Akhter S, 1998, J BIOCHEM-TOKYO, V123, P1127
[2]
Choudhuri R, 1997, CANCER RES, V57, P1814
[3]
Neointima formation in a restenosis model is suppressed in midkine-deficient mice [J].
Horiba, M ;
Kadomatsu, K ;
Nakamura, E ;
Muramatsu, H ;
Ikematsu, S ;
Sakuma, S ;
Hayashi, K ;
Yuzawa, Y ;
Matsuo, S ;
Kuzuya, M ;
Kaname, T ;
Hirai, M ;
Saito, H ;
Muramatsu, T .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (04) :489-495
[4]
Serum midkine levels are increased in patients with various types of carcinomas [J].
Ikematsu, S ;
Yano, A ;
Aridome, K ;
Kikuchi, M ;
Kumai, H ;
Nagano, H ;
Okamoto, K ;
Oda, M ;
Sakuma, S ;
Aikou, T ;
Muramatsu, H ;
Kadomatsu, K ;
Muramatsu, T .
BRITISH JOURNAL OF CANCER, 2000, 83 (06) :701-706
[5]
CDNA CLONING AND SEQUENCING OF A NEW GENE INTENSELY EXPRESSED IN EARLY DIFFERENTIATION STAGES OF EMBRYONAL CARCINOMA-CELLS AND IN MID-GESTATION PERIOD OF MOUSE EMBRYOGENESIS [J].
KADOMATSU, K ;
TOMOMURA, M ;
MURAMATSU, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 151 (03) :1312-1318
[6]
Midkine induces the transformation of NIH3T3 cells [J].
Kadomatsu, K ;
Hagihara, M ;
Akhter, S ;
Fan, QW ;
Muramatsu, H ;
Muramatsu, T .
BRITISH JOURNAL OF CANCER, 1997, 75 (03) :354-359
[7]
Kaneda N, 1996, J BIOCHEM-TOKYO, V119, P1150
[8]
Cortactin-Src kinase signaling pathway is involved in N-syndecan-dependent neurite outgrowth [J].
Kinnunen, T ;
Kaksonen, M ;
Saarinen, J ;
Kalkkinen, N ;
Peng, HB ;
Rauvala, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (17) :10702-10708
[9]
Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor [J].
Kojima, T ;
Katsumi, A ;
Yamazaki, T ;
Muramatsu, T ;
Nagasaka, T ;
Ohsumi, K ;
Saito, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (10) :5914-5920
[10]
KOSHIISHI I, 1993, BIOL PHARM BULL, V16, P307